Search Result

Results for "

URAT1 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	URAT1 (38) Apoptosis (1) Cytochrome P450 (2) GLUT (8) Interleukin Related (3) Isotope-Labeled Compounds (1) NF-κB (1) NOD-like Receptor (NLR) (2) OAT (7) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Reverse Transcriptase (1) TNF Receptor (2) TRP Channel (1) Xanthine Oxidase (5)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Endocrinology (2) Infection (2) Inflammation/Immunology (18) Metabolic Disease (26) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: URAT1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15258

Lesinurad 5 Publications Verification RDEA594	OAT URAT1	Metabolic Disease
Lesinurad is a *URAT1* and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with K_m values of 0.85 and 2 µM, respectively.

HY-16733

Verinurad 2 Publications Verification RDEA3170	URAT1	Metabolic Disease
Verinurad (RDEA3170) is a highly potent and specific *URAT1* inhibitor with an IC₅₀ of 25 nM .

HY-147422

Xininurad XNW3009	URAT1	Metabolic Disease Inflammation/Immunology
Xininurad is a potent orally active *URAT1* inhibitor with an IC₅₀ of 7.17 nM. Xininurad inhibits *URAT1* activity to reduce serum uric acid levels and increase urinary uric acid excretion. Xininurad can be used for the research of hyperuricemia and gout .

HY-15258A

Lesinurad sodium 5 Publications Verification RDEA-594 sodium	OAT URAT1	Metabolic Disease
Lesinurad sodium is a *URAT1* and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with K_m values of 0.85 and 2 μM, respectively.

HY-153971

URAT1 inhibitor 8	URAT1	Metabolic Disease
URAT1 inhibitor 8 (example 247) is a potent *URAT1* inhibitor, with an IC₅₀ of 0.001 μM. URAT1 inhibitor 8 can be used for gout research .

HY-163431

URAT1 inhibitor 10	URAT1	Inflammation/Immunology
URAT1 inhibitor 10 (Compound 23a) is a *URAT1* inhibitor. URAT1 inhibitor 10 has oral efficacy and low cytotoxicity. URAT1 inhibitor 10 has high selectivity for OAT1 .

HY-153706

URAT1 inhibitor 5	URAT1	Cardiovascular Disease Metabolic Disease
URAT1 inhibitor 5 (compound 16) is a potent *URAT1* inhibitor. URAT1 inhibitor 5 can be used in research of hyperuricemia .

HY-176139

URAT1 inhibitor 13	URAT1	Inflammation/Immunology
URAT1 inhibitor 13 (compound 22k) is a potent *URAT1* inhibitor. URAT1 inhibitor 13 can be used in the study of gout .

HY-151432

URAT1 inhibitor 3	URAT1	Inflammation/Immunology
URAT1 inhibitor 3 is a potent, orally active, selective *URAT1* inhibitor with an IC₅₀ value of 0.8 nM. URAT1 inhibitor 3 has urate-lowering efficacy. URAT1 inhibitor 3 can be used in research of gout and hyperuricemi .

HY-153970

URAT1 inhibitor 7	URAT1	Inflammation/Immunology
URAT1 inhibitor 7 (compound 10f) is a potent *URAT1* inhibitor, with an IC₅₀ of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits CYP2C9, with an IC₅₀ of 4.2 μM. URAT1 inhibitor 7 can be used for gout research .

HY-111345

Epaminurad UR-1102; URC-102	OAT URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) is an orally active, potent and selective *URAT1* (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research .

HY-114309

URAT1 inhibitor 1	URAT1	Inflammation/Immunology
URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC₅₀ of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout .

HY-153969

URAT1 inhibitor 6	URAT1	Inflammation/Immunology
URAT1 inhibitor 6 (Compound 1h) is a potent *URAT1* inhibitor (IC₅₀: 35 nM for hURAT1). URAT1 inhibitor 6 is 200- and 8-fold more potent than parent Lesinurad (HY-15258) and Benzbromarone (HY-B1135). URAT1 inhibitor 6 can be used for research of inflammation .

HY-160265

URAT1 inhibitor 9	URAT1	Inflammation/Immunology
URAT1 inhibitor 9 (Compound 24) is an *URAT1* inhibitor that can be used in the study of gout or hyperuricemia .

HY-143906

URAT1 inhibitor 2	URAT1	Inflammation/Immunology
URAT1 inhibitor 2 is an orally active and potent *URAT1* and CYP isozyme inhibitor, with IC₅₀ values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated ¹⁴C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout .

HY-152033

URAT1 inhibitor 4	URAT1 GLUT	Metabolic Disease
URAT1 inhibitor 4, a Lesinurad derivative, is a potent and orally active *URAT1* inhibitor with an IC₅₀ of 7.56 μM. URAT1 inhibitor 4 has higher in vivo urate-lowering efficacy than Lesinurad (HY-15258) .

HY-168740

URAT1 inhibitor 11	URAT1	Metabolic Disease
URAT1 inhibitor 11 (Compound 7) is a *URAT1* inhibitor with an IC₅₀ value of 0.18 μM. URAT1 inhibitor 11 exhibits potent hypouricemic effects in hyperuricemic zebrafish induced by Potassium oxonate (HY-17511) and Xanthine sodium salt (HY-W017389) .

HY-175645

NLRP3/URAT1-IN-1	NOD-like Receptor (NLR) URAT1 Interleukin Related OAT GLUT	Metabolic Disease Inflammation/Immunology
NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and *URAT1* (IC₅₀ = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC₅₀ of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia .

HY-116694

Digallic acid	Apoptosis Reactive Oxygen Species (ROS) Reverse Transcriptase Xanthine Oxidase URAT1	Infection Metabolic Disease Inflammation/Immunology Cancer
Digallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, *URAT1* (IC₅₀: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus .

HY-153972

URAT1&XO inhibitor 2	URAT1 Xanthine Oxidase	Metabolic Disease Inflammation/Immunology
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and *URAT1, with IC₅₀* of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a K_i value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia .

HY-158056

URAT1/GLUT9-IN-1	GLUT URAT1	Metabolic Disease
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC₅₀=2.01 μM) and glucose transporter 9 (GLUT9) (IC₅₀=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .

HY-153968

URAT1&XO inhibitor 1	Xanthine Oxidase URAT1	Metabolic Disease
URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC₅₀=~10 μM) and Xanthine Oxidase (IC₅₀=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research .

HY-159581

URAT1&XO inhibitor 3	URAT1	Others
URAT1&XO inhibitor 3 (compound 27) is an orally active anti-gout agent targeting XO (IC₅₀: 35 nM) and *URAT1* (IC₅₀: 31 nM). URAT1&XO inhibitor 3 has good pharmacological and pharmacokinetic (PK) characteristics and in vivo safety .

HY-157306

HC-1310	URAT1	Metabolic Disease
HC-1310 URAT1 Inhibitor (Compound 83) is a potent *URAT1* inhibitor and can be used for research on hyperuricemia and gout .

HY-144305

KPH2f	URAT1 GLUT	Infection
KPH2f is a safe, orally active, and effective dual *URAT1/GLUT9* inhibitor with IC₅₀s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively. KPH2f shows little effects on OAT1 and ABCG2 (IC₅₀=32.14 and 26.74 μM) .

HY-111345A

Epaminurad hydrochloride UR-1102 hydrochloride; URC-102 hydrochloride	OAT URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) hydrochloride is an orally active, potent and selective *URAT1* (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad hydrochloride quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad hydrochloride is a uricosuric agent. Epaminurad hydrochloride can be used for gout and hyperuricemia research .

HY-172774

TRPV1 antagonist 10	TRP Channel URAT1 GLUT Cytochrome P450 Interleukin Related TNF Receptor	Neurological Disease Inflammation/Immunology Endocrinology
TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist (IC₅₀ = 33.06 nM), moderate to weak *URAT1* (IC₅₀ = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor. TRPV1 antagonist 10 has analgesic and urate-lowering effect. TRPV1 antagonist 10 can be studied for research in hyperuricemia and inflammatory pain .

HY-172778

HNW005	NOD-like Receptor (NLR) URAT1	Metabolic Disease Inflammation/Immunology
HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1). It has a K_D value of 204.6 nM and an IC₅₀ of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC₅₀ of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis .

HY-161523

XOR/URAT1-IN-1	Xanthine Oxidase URAT1	Metabolic Disease
XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC₅₀ of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model .

HY-101439

JTT-552	URAT1	Others
JTT-552 is a compound targeting URAT1 with activity in inhibiting hyperuricemia and gout.

HY-16733R

Verinurad (Standard) RDEA3170 (Standard)	URAT1 Reference Standards	Metabolic Disease
Verinurad (Standard) is the analytical standard of Verinurad. This product is intended for research and analytical applications. Verinurad (RDEA3170) is a highly potent and specific URAT1 inhibitor with an IC50 of 25 nM .

HY-15258S1

Lesinurad-d4 RDEA594-d₄	Isotope-Labeled Compounds URAT1 OAT	Metabolic Disease
Lesinurad-d₄ (RDEA594-d₄) is deuterium labeled Lesinurad. Lesinurad is a *URAT1* and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with K_m values of 0.85 and 2 μM, respectively.

HY-175309

URAT1-IN-14	URAT1	Metabolic Disease
URAT1-IN-14 is a potent and orally active Urate transporter 1 (URAT1) inhibitor. URAT1-IN-14 inhibits the human URAT1 in HEK293 cells with an IC₅₀ of 0.72 μM. URAT1-IN-14 exhibits low cytotoxic in Hep-G2 cells. URAT1-IN-14 shows urate-lowering effect in hyperuricemia mouse models. URAT1-IN-14 can be used for the study of hyperuricemia and gout .

HY-180227

URAT1-IN-15	URAT1 OAT Cytochrome P450	Metabolic Disease
URAT1-IN-15 (Compound 9) is an orally active, selective *URAT1* inhibitor with an IC₅₀ of 69.81 nM. URAT1-IN-15 inhibits CYP2C9 (IC₅₀ = 8.39 μM). URAT1-IN-15 shows uricosuric activity. URAT1-IN-15 can be used in the research of hyperuricemia .

HY-183658

URAT1/GLUT9-IN-3	URAT1 GLUT	Metabolic Disease Inflammation/Immunology
URAT1/GLUT9-IN-3 is an orally active *URAT1/GLUT9* dual inhibitor with IC₅₀ values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia .

HY-183543

URAT1/GLUT9-IN-2	URAT1 GLUT	Metabolic Disease Endocrinology
URAT1/GLUT9-IN-2 is a selective, orally active *URAT1/GLUT9* inhibitor, with an IC₅₀ of 2.81 μM against *URAT1* and an IC₅₀ of 12.53 μM against GLUT9. URAT1/GLUT9-IN-2 reduces serum uric acid levels and protects renal function. URAT1/GLUT9-IN-2 can be used in research related to hyperuricemia and hyperuricemic nephropathy .

HY-182294

HYJ-2	URAT1	Metabolic Disease Inflammation/Immunology
HYJ-2 is a *URAT1* inhibitor and urate-lowering agent. HYJ-2 inhibits *URAT1*-mediated urate transport and interacts with key residues within the *URAT1* binding pocket. HYJ-2 reduces serum urate levels in hyperuricemic mice without inducing liver or kidney injury. HYJ-2 shows low cytotoxicity to hepatocytes and renal cells. HYJ-2 does not significantly induce hepatocyte apoptosis or mitochondrial dysfunction. HYJ-2 can be used in studies related to hyperuricemia and gout .

HY-180271

Xanthine oxidase-IN-21	Xanthine Oxidase NF-κB TNF Receptor Interleukin Related URAT1 GLUT	Metabolic Disease
Xanthine oxidase-IN-21, a Genipin (HY-17389) derivative, is an orally active mixed competitive xanthine oxidase (XOD) inhibitor with an IC₅₀ of 0.68 μM. Xanthine oxidase-IN-21 reduces renal fibrosis by decreasing α-SMA expression and suppresses pro-inflammatory cytokines IL-1β, IL-6, and TNF-α through NF-κB pathway regulation. Xanthine oxidase-IN-21 also inhibits *URAT1* and GLUT9 expression, promoting uric acid excretion and lowering serum uric acid levels. Xanthine oxidase-IN-21 shows significantly hepatorenal protection activity. Xanthine oxidase-IN-21 can be used for the research of hyperuricemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-116694

Digallic acid	Pistacia lentiscus var. Chia Phenols Polyphenols Plants Anacardiaceae Source Classification	Apoptosis Reactive Oxygen Species (ROS) Reverse Transcriptase Xanthine Oxidase URAT1
Digallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, *URAT1* (IC₅₀: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus .

Cat. No.	Product Name	Chemical Structure

HY-15258S1

Lesinurad-d4
Lesinurad-d₄ (RDEA594-d₄) is deuterium labeled Lesinurad. Lesinurad is a *URAT1* and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with K_m values of 0.85 and 2 μM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

URAT1 Inhibitor

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products